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Background and purpose: Studies investigating the association between 25-
hydroxyvitamin D [25(OH)D] and cognition in the very old (85+) are lacking.
Methods: Cross-sectional (baseline) and prospective data (up to 3 years fol-
low-up) from 775 participants in the Newcastle 85+ Study were analysed for
global (measured by the Standardized Mini-Mental State Examination) and
attention-speciﬁc (measured by the attention battery of the Cognitive Drug
Research test) cognitive performance in relation to season-speciﬁc 25(OH)D
quartiles.
Results: Those in the lowest and highest season-speciﬁc 25(OH)D quartiles
had an increased risk of impaired prevalent (1.66, 95% conﬁdence interval
1.06–2.60, P = 0.03; 1.62, 95% conﬁdence interval 1.02–2.59, P = 0.04, respec-
tively) but not incident global cognitive functioning or decline in functioning
compared with those in the middle quartiles adjusted for sociodemographic,
health and lifestyle confounders. Random eﬀects models showed that partici-
pants belonging to the lowest and highest 25(OH)D quartiles, compared with
those in the middle quartiles, had overall slower (log-transformed) attention
reaction times for Choice Reaction Time (lowest, b = 0.023, P = 0.01; highest,
b = 0.021, P = 0.02), Digit Vigilance Task (lowest, b = 0.009, P = 0.05; high-
est, b = 0.01, P = 0.02) and Power of Attention (lowest, b = 0.017, P = 0.02;
highest, b = 0.022, P = 0.002) and greater Reaction Time Variability (lowest,
b = 0.021, P = 0.02; highest, b = 0.02, P = 0.03). The increased risk of worse
global cognition and attention amongst those in the highest quartile was not
observed in non-users of vitamin D supplements/medication.
Conclusion: Low and high season-speciﬁc 25(OH)D quartiles were associated
with prevalent cognitive impairment and poorer overall performance in atten-
tion-speciﬁc tasks over 3 years in the very old, but not with global cognitive
decline or incident impairment.
Introduction
Recent evidence from life sciences and epidemiology
points to the role of serum 25-hydroxyvitamin D [25
(OH)D] in brain function, including cognition, across
the life span [1,2]. Detection of hydroxylases for vita-
min D activation and vitamin D receptors in neurons
and glia in brain regions essential for cognition and
memory implicates their relevance for brain health.
Moreover, in vitro and in vivo studies propose neuro-
protective properties of 25(OH)D [2].
Current epidemiological research suggests an inverse
or non-linear (i.e. curvilinear or U-shaped) association
between circulating 25(OH)D concentration and risk
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of several age-related chronic diseases and all-cause
mortality [3–8], suggesting beneﬁcial health outcomes
at moderate (~50–60 nM) or higher concentrations
(~75–80 nM). Based on skeletal health [7], it has been
estimated that 50 nM (20 ng/ml) of 25(OH)D meets
the requirements of >97.5% of the US population
across all age groups. However, a number of studies
have demonstrated a high prevalence of 25(OH)D
inadequacy amongst older adults based on a clinical
threshold of 25 or 30 nM [9,10]. A higher risk of low
vitamin D status (<25 nM) in older adults has been
linked to reduced epidermal stores of 7-dehydro-
cholesterol (vitamin D precursor), immobility, malnu-
trition, renal impairment and environmental factors
[10,11]. However, current scientiﬁc evidence is inade-
quate to allow the development of recommendations
for optimal age-speciﬁc 25(OH)D concentrations, or
clinical thresholds, for extra-skeletal health in older
adulthood. There is also uncertainty about the utility
of vitamin D supplementation, especially for those
aged 75+ living with comorbidities [7,11,12]. Although
recent evidence indicates that supplementation
improves vitamin D status in older adults without
adversely aﬀecting heath and survival [13], there is no
consensus on the deﬁnition of hypovitaminosis D and
upper 25(OH)D thresholds for optimum physical and
mental health in old age to prevent problems with
under- or over-treatment [7,11,12,14].
Non-optimal concentration of 25(OH)D, variously
deﬁned as <25 nM (10 ng/ml) or <50 nM (20 ng/ml),
has been implicated as a risk factor for global cogni-
tive impairment [15,16] and weaker performance on
domain-speciﬁc cognitive tasks [17–20] in several, but
not all, cross-sectional studies [21] involving adults
aged 60+. Only four prospective studies reported an
increased risk of cognitive decline in association with
lower concentrations of serum 25(OH)D (≤50 nM) in
adults aged 65+ [22–25]. Studies on 25(OH)D and
cognitive decline in those aged 85+ are scarce [26,27].
The Newcastle 85+ Study was therefore used to test
for the presence of either an inverse or a non-linear
association between 25(OH)D concentrations and cog-
nition at baseline and cognitive decline over 3 years,
utilizing measures of global and attention-speciﬁc cog-
nitive function.
Method
Participants
Participants were drawn from the Newcastle 85+
Study, a longitudinal study of health trajectories and
outcomes in a single-year birth cohort (1921)
recruited from general practices in Newcastle and
North Tyneside, UK, as described elsewhere [28,29].
The study was approved by the Newcastle and North
Tyneside Local Research Committee One. At baseline
(20062007), both multidimensional health assess-
ment and general practice records data were available
for 845 individuals who formed the basis for this
analysis. Serum 25(OH)D was successfully measured
from blood samples in 775 (91.7%) individuals [30].
Participants were followed up at 1.5 and 3 years.
Cognitive assessments
Global cognitive function was evaluated using the
Standardized Mini-Mental State Examination
(SMMSE), a brief dementia-screening instrument
which provides a global score of cognitive function
ranging from 0 to 30 points [31] that correlates well
with performance in activities of daily living [31,32].
In all, 773 (91.5%) participants with a baseline
SMMSE score and 25(OH)D status formed our ana-
lytical sample (Fig. S1). Cognitive status was deﬁned
as normal (SMMSE scores ≥26) or impaired (SMMSE
scores ≤25) [31,32] at baseline and 3-year follow-up.
Incident cognitive impairment was deﬁned as crossing
the 25-point threshold of the SMMSE [32]. Models in
which cognitive decline was deﬁned as a loss of ≥3
points from the baseline score (i.e. clinically meaning-
ful or reliable change) [33,34] were also considered.
Attention was measured using the attention subsets
of the Cognitive Drug Research (CDR) computerized
assessment system [35,36] (see Method S1 for details),
comprising mean reaction times (speed scores) of cor-
rect responses (in ms) for Simple Reaction Time
(SRT), Choice Reaction Time (CRT) and Digit Vigi-
lance Task (DVT). SRT measures alertness and con-
centration; CRT examines similar abilities including
the extra time taken to discriminate between two
opposing stimuli (i.e. reﬂecting the additional informa-
tion processing in this task); and DVT tests sustained
attention whilst ignoring distractors. Additionally three
validated composite measures derived from these tasks
were used: Power of Attention (PoA), a sum of the
three attention speed scores, measures the intensity of
concentration and the ability to focus attention [37];
Reaction Time Variability (RTV), a sum of coeﬃcients
of variance of the three speed scores, measures ﬂuctua-
tion in attention [38,39]; and Continuity of Attention
(CoA), a combination of the accuracy scores from
CRT and DVT, assesses the ability to sustain attention
over the testing period [39]. Details of how composite
measures were constructed and their validation process
are described in Method S1. For all attention-speciﬁc
measures except CoA, lower scores indicate better
performance. A total of 761 participants had at least
© 2014 The Author(s).
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one attention task score at baseline. A training session
1 week prior to baseline measurements was undertaken
with 91.5% (n = 773) of participants [40].
Serum 25(OH)D assay
Serum 25(OH)D was obtained from fasting morning
blood samples and measured by the DiaSorin Radioim-
mune Assay kit as described [30] (see Method S2 for
details). The mean (SD) time between cognitive testing
and blood sampling was 0.28 (0.59) months. Because of
seasonal variation in 25(OH)D concentration [41], the
season of blood draw [December–February (Winter),
March–May (Spring), June–August (Summer), and
September–November (Autumn)] was controlled for by
creating season-speciﬁc quartiles (SQ1–SQ4) [42] with
cut-oﬀs of 5–17 nM (Spring) to 8–20 nM (Autumn) for
SQ1, 18–26 nM (Spring) to 29–45 nM (Summer)
for SQ2, 27–46 nM (Spring) to 46–68 nM (Summer)
for SQ3 and ≥47 nM (Spring) to ≥69 nM (Summer) for
SQ4 (for details see Method S3). The middle quartiles
(SQ2 and SQ3) were combined and used as the refer-
ent, thus generating three season-speciﬁc 25(OH)D
groups: lowest, middle and highest.
Other measures/confounders
Confounders used in the above reported studies
[16,22,23,25] were considered for inclusion in the mod-
els (see Method S4 for details). Brieﬂy, socio-
demographic factors (sex, education, income), health
and morbidity [individual chronic diseases: cardiovas-
cular diseases (includes hypertension, cardiac disease
and peripheral vascular disease), cerebrovascular dis-
eases, diabetes, osteoporosis; or total number of
chronic diseases, renal impairment, depression, waist-
hip ratio, serum vitamin B12 and folate), and life-
style factors (smoking, alcohol and physical activity)
were included. Because the intake of supplements and
medication containing vitamin D was regarded as an
important biological determinant of 25(OH)D status
in this population, separate analyses were conducted
with the entire cohort and with a ‘restricted cohort’
(i.e. excluding 167 (19.8%) individuals who were tak-
ing vitamin D supplements/medication).
Statistical analysis
Participants (n = 845) were compared across the three
season-speciﬁc 25(OH)D groups by Kruskal–Wallis
tests for ordered and non-normally distributed contin-
uous variables and v2 tests for categorical variables.
For several confounders, missing values were imputed
to the reference value to allow for comparison of
nested models. Several logistic regression models were
ﬁtted to explore the association between season-
speciﬁc 25(OH)D groups and prevalent cognitive
impairment (odds ratio, 95% conﬁdence interval).
Models were unadjusted (model 1), adjusted for sex
and education (model 2) and adjusted for all con-
founders (model 3). The models were then ﬁtted with
incident cognitive impairment deﬁned as converting
from normal to impaired cognitive status at 3-year
follow-up. Cognitive status 3 years post baseline was
also examined, and cognitive decline of ≥3 points as
an outcome was used to determine a clinically mean-
ingful/reliable change in the SMMSE [33,34].
All attention reaction times were converted into
seconds and logarithmically (log10) transformed to
correct a positive skew, and to aid convergence. PoA
and RTV were also log10 transformed, whereas CoA
was negatively skewed and corrected as
NEWX = SQRT(K  X) in which K = maximum
score + 1. Using all available data for 845 partici-
pants, multilevel linear modelling [43] was conducted
to determine the eﬀect of 25(OH)D on initial level
and rate of change over 3 years in attention-speciﬁc
tasks, and a series of linear growth curve models were
ﬁtted as follows: (i) with ‘time’ in the study (to exam-
ine the linear trend of time) and season-speciﬁc 25
(OH)D groups [to test whether initial status (intercept)
varied by 25(OH)D] (model 1); (ii) with an interaction
of season-speciﬁc 25(OH)D groups and time [to test
for varying rates of change by 25(OH)D] (model 2);
and (iii) with further adjustment for confounders asso-
ciated with cognition and 25(OH)D levels (model 3).
The SPSS MIXED procedure (SPSS, IBM Corpora-
tion, Armonk, NY, USA), with restricted maximum
likelihood method and autoregressive error covariance
matrix was used to generate parameter estimates (b)
for eﬀects.
A number of sensitivity analyses of the 25(OH)D
groups in relation to cognitive outcomes were under-
taken. The analyses were repeated deﬁning cognitive
change as scoring 1 SD and 1.5 SD below the
mean and using ≤23 SMMSE points for cognitive
impairment (Method S5). The analyses were also
repeated excluding participants with a diagnosis of
dementia, and whether ﬁndings were due to terminal
drop was explored.
Results
Baseline characteristics of the participants by 25(OH)D
groups
Participants in the middle season-speciﬁc 25(OH)D
group (SQ2 and SQ3 combined) were the least
© 2014 The Author(s).
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depressed and the most physically active, whilst those
in the highest quartile (SQ4) were more likely to be
female, to take prescribed vitamin D, to have osteopo-
rosis, and to have the highest levels of serum folate
compared with participants in the other groups (Table S1).
Compared with the middle group, those belonging to
the lowest (SQ1) and/or highest (SQ4) season-speciﬁc
25(OH)D groups had more cognitive impairment (≤25
SMMSE score) (H(2) = 26.55, P < 0.001) and had
worse reaction times on DVT (H(2) = 8.91, P = 0.01),
PoA (H(2) = 8.74, P = 0.01), RTV (H(2) = 7.73,
P = 0.02) and CoA (H(2) = 10.51, P = 0.005) (Table 1).
25(OH)D and prevalent global cognitive impairment
(SMMSE)
Of 773 participants with baseline cognitive and 25
(OH)D status used in the logistic regression models
(Fig. S1), 212 (27.4%) were classiﬁed as impaired
(SMMSE ≤ 25, [31,32]). After adjustment for sex, edu-
cation, health and lifestyle factors (model 3), partici-
pants in the lowest and highest season-speciﬁc 25(OH)
D groups had increased odds of cognitive impairment
compared with participants belonging to the middle
group (odds ratio 1.66, 95% conﬁdence interval
1.06–2.60, P = 0.03, and 1.62, 1.02–2.59, P = 0.04,
respectively) (Table 2). In the ‘restricted cohort’, only
associations between the lowest 25(OH)D group and
global cognitive functioning remained (1.73, 1.09–
2.75, P = 0.02).
25(OH)D and incident cognitive impairment over
3 years
Compared with participants who had SMMSE data
3 years later (n = 470), those lost to follow-up
Table 1 Global cognitive and attention scoresa of participants in the Newcastle 85+ Study by season-speciﬁc 25(OH)D groupsb at baseline and
follow-up
Cognitive domain/scores All participants
Lowest season-speciﬁc
25(OH)D group
Middle season-speciﬁc
25(OH)D group
Highest season-speciﬁc
25(OH)D group P valuec
Cognitive status by SMMSE
Baseline (n) 839 191 392 190
Total SMMSE (mean, SD) 25.9 (5.3) 25.0 (5.9) 27.0 (3.6) 25.4 (5.9) <0.001
Impaired (≤25 SMMSE score %, n) 28.6 (240) 37.7 (72) 19.4 (76) 33.7 (64) <0.001
Normal (26–30) 71.4 (599) 62.3 (119) 80.6 (316) 66.3 (126)
Follow-up at 3 years (n) 470 101 248 103
Total SMMSE (mean, SD) 25.4 (5.5) 24.0 (6.4) 26.1 (4.6) 25.4 (5.6) 0.005
Impaired (≤25 SMMSE score %, n) 34.0 (160) 47.5 (48) 29.8 (74) 30.1 (31) 0.004
Normal (26–30) 66.0 (310) 52.5 (53) 70.2 (174) 69.9 (72)
CDR Attention Battery
baseline (n) 761 177 373 176
SRT (ms, mean, SD) 475.4 (488.0) 509.1 (540.6) 459.5 (548.4) 470.1 (234.7)
CRT (ms, mean, SD) 650.6 (350.7) 687.6 (360.6) 623.0 (340.6) 658.0 (251.6)
DVT (ms, mean, SD) 526.0 (69.9) 534.8 (73.0) 518.5 (65.5) 535.5 (76.0) 0.01
PoA (ms, mean, SD) 1618.3 (583.7) 1700.4 (846.1) 1549.4 (337.6) 1663.4 (490.2) 0.01
RTV (mean, SD)d 64.3 (19.9) 66.7 (21.5) 62.7 (19.2) 65.3 (20.1) 0.02
CoA (mean, SD)e 51.4 (9.6) 50.3 (9.7) 52.4 (8.4) 51.6 (10.3) 0.005
Follow-up at 1.5 years (n) 570 127 284 130
SRT (ms, mean, SD) 491.4 (314.1) 500.4 (315.0) 471.5 (290.3) 517.3 (357.6)
CRT (ms, mean, SD) 669.0 (311.5) 698.1 (317.8) 642.4 (290.3) 681.3 (268.7) 0.03
DVT (ms, mean, SD) 532.7 (73.8) 541.8 (70.1) 528.2 (70.7) 532.4 (80.5)
PoA (ms, mean, SD) 1691.7 (622.6) 1738.4 (653.4) 1642.1 (563.6) 1727.3 (624.0)
RTV (mean, SD) 64.4 (21.7) 66.7 (24.7) 62.1 (18.0) 65.6 (23.4) 0.02
CoA (mean, SD) 51.6 (8.5) 50.3 (9.8) 52.2 (7.4) 52.3 (8.1) 0.005
Follow-up at 3 years (n) 416 87 222 92
SRT (ms, mean, SD) 475.3 (251.4) 509.5 (303.8) 454.6 (181.9) 498.1 (339.1)
CRT (ms, mean, SD) 677.9 (368.9) 727.6 (445.2) 649.2 (327.1) 709.2 (403.6)
DVT (ms, mean, SD) 533.8 (73.6) 540.8 (69.9) 531.9 (72.5) 531.7 (80.9)
PoA (ms, mean, SD) 1687.5 (620.8) 1777.9 (754.7) 1635.6 (510.5) 1741.3 (745.2)
RTV (mean, SD) 63.4 (21.1) 62.2 (17.9) 62.6 (21.8) 65.2 (21.5)
CoA (mean, SD) 51.7 (8.7) 51.5 (7.7) 52.1 (8.2) 51.9 (9.5)
SMMSE, Standardized Mini-Mental State Examination; CDR, cognitive drug research; SRT, simple reaction time; CRT, choice reaction time;
DVT, digit vigilance task; PoA, power of attention. aUntransformed scores; bseason-speciﬁc quartiles were derived for each season of blood
draw and combined to create season-speciﬁc 25(OH)D groups (SQ1SQ4); middle quartiles were collapsed (SQ2 and SQ3) and served as a ref-
erent; cKruskal–Wallis test for ordered and non-normally distributed continuous variables; dRTV, reaction time variability, expressed as coeﬃ-
cient of variation; eCoA, continuity of attention, expressed in CoA arbitrary units.
© 2014 The Author(s).
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[n = 375 (44.4%); of whom 360 died and 15 did not
complete the follow-up SMMSE] had fewer sources of
retirement income (P = 0.02), were less physically
active (P < 0.001), had more depressive symptoms
(P = 0.007) and chronic diseases (P = 0.006), and
were more likely to be cognitively impaired at baseline
(P < 0.001). Participants who remained in the study
were more likely to take other vitamin supplements
(P = 0.001) but not prescribed vitamin D medication
(P = 0.001) and were more likely to drink alcohol
(P < 0.001). The groups did not diﬀer on serum 25
(OH)D status (P = 0.94).
At the 3-year follow-up, 299 (66.2%) participants
with 25(OH)D status were cognitively intact (SMMSE
≥ 26) and 153 (33.8%) were cognitively impaired
(SMMSE ≤ 25) (Fig. S1). Of those cognitively intact
at baseline, with established 25(OH)D status and with
follow-up SMMSE (n = 362), 82 (22.7%) decreased
by ≥1 point and crossed the 25-point threshold. Simi-
lar models as for prevalent cognitive impairment were
used to investigate the relationship between season-
speciﬁc 25(OH)D groups and incident cognitive
decline (Table 3), but there was no evidence of a sig-
niﬁcant eﬀect of 25(OH)D. These conclusions
remained for fully adjusted models when the outcome
was deﬁned as global cognitive status 3 years later
(Table S2), as a decline of ≥3 points of the SMMSE,
as a decline of 1.0 SD or 1.5 SD below the mean
using a 23-point cut-oﬀ to deﬁne cognitive impair-
ment, as continuous outcome (i.e. diﬀerence scores),
or when analyses were additionally controlled for vital
status (dead or alive 2 years after the 3-year follow-
up) to exclude possible terminal decline (data not
shown).
25(OH)D and attention (CDR attention battery)
The associations between season-speciﬁc 25(OH)D
groups and attention reaction times and attention-
speciﬁc composite scores at baseline and at 1.5- and
3-year follow-ups were examined through multilevel
models. All attention-speciﬁc reaction times (includ-
ing information processing speed) showed a signiﬁ-
cant increase over 3 years (i.e. slower or poorer
performance) after adjustment for potential con-
founders (Table 4). The linear growth rate for SRT,
CRT, DVT and PoA reaction times increased (slo-
wed) signiﬁcantly by 0.028, 0.021, 0.009 and 0.023
log-transformed (mean) seconds per unit of time,
respectively (Table 4, model 3). CoA (sustained
attention) declined over time (i.e. negative b esti-
mates in models with untransformed scores; data
not shown). No linear time trend level was evident
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for RTV, indicating little or no within-person
change over 3 years.
Initial status (intercept) for all attention outcomes
varied signiﬁcantly by season-speciﬁc 25(OH)D quar-
tiles (model 1) but the rate of change in attention
(slope) showed no eﬀect (models 2 and 3). Speciﬁcally,
after adjustment for sex, education, lifestyle factors
and number of chronic conditions (model 3), both the
lowest and highest quartiles of 25(OH)D were associ-
ated with overall slower reaction times and informa-
tion processing speed in CRT and DVT and with
increased PoA (i.e. focused attention/intensity of con-
centration) and RTV scores (i.e. greater ﬂuctuation in
attention) compared with the middle quartile. The
log-transformed means of DVT sustained attention
speed were slower by 0.009 s (P = 0.05) and by 0.010
s (P = 0.002) for participants belonging to the lowest
and highest 25(OH)D quartiles, respectively. The log-
transformed RTV coeﬃcients of variance were higher
by 0.021 (P = 0.02) for those in the lowest quartile
and by 0.020 (P = 0.03) for participants in the highest
25(OH)D quartile, indicating greater ﬂuctuation in
attention compared with participants in the middle 25
(OH)D group. A signiﬁcant eﬀect of highest 25(OH)D
quartile on PoA [b (SE) = 0.022 (0.007), P = 0.002]
but not on CoA (P = 0.14) was also observed, sug-
gesting that the overall change in PoA speed amongst
these participants was independent of the poorer abil-
ity to sustain attention/accuracy. A non-signiﬁcant
time by 25(OH)D group interaction for all outcomes
and models indicated that the slopes (rate of change)
did not vary by 25(OH)D quartile between individuals
over the study period (Table 4). In the ‘restricted
cohort’, similar conclusions regarding 25(OH)D and
attention-speciﬁc outcomes held for the lowest but not
the highest 25(OH)D group (Table S3).
Discussion
In this prospective, population-based study of older
adults aged 85+, it was found that both low and high
season-speciﬁc quartiles of 25(OH)D were associated
with higher odds of prevalent cognitive impairment
(assessed by SMMSE), poorer attention reaction
times/processing speed and focused attention/concen-
tration, and greater attention ﬂuctuation (assessed by
CDR). Diﬀerences remained signiﬁcant after adjust-
ment for sex, education, lifestyle factors and the pres-
ence of several chronic diseases, although eﬀects were
small. In the fully adjusted model the harmful eﬀect
of the highest season-speciﬁc 25(OH)D quartile on
focused attention (PoA) seemed to be independent of
the ability to sustain attention/accuracy (CoA), sug-
gesting no concentrationaccuracy trade-oﬀs. How-Ta
b
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Table 4 Parameter estimatesa of growth curve models for attention tasks over 3 years by season-speciﬁc 25(OH)D groupsb (entire cohort)
Outcome Eﬀects
Model 1
b (SE) P
Model 2
b (SE) P
Model 3
b (SE) P
SRT Time 0.029 (0.005) <0.001 0.028 (0.007) <0.001 0.028 (0.007) <0.001
Intercept 25(OH)D
Lowest 0.031 (0.011) 0.006 0.030 (0.012) 0.009 0.02 (0.012) 0.09
Middle (ref.) 0.0 0.0 0.0
Highest 0.025 (0.011) 0.03 0.025 (0.012) 0.03 0.023 (0.012) 0.05
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.004 (0.013) 0.75 0.004 (0.013) 0.74
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.002 (0.013) 0.90 0.002 (0.012) 0.85
CRT Time 0.025 (0.004) <0.001 0.021 (0.006) <0.001 0.021 (0.006) <0.001
Intercept 25(OH)D
Lowest 0.032 (0.009) 0.001 0.031 (0.009) 0.001 0.023 (0.009) 0.01
Middle (ref.) 0.0 0.0 0.0
Highest 0.026 (0.009) 0.006 0.025 (0.009) 0.007 0.021 (0.009) 0.02
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.005 (0.010) 0.65 0.007 (0.010) 0.48
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.009 (0.010) 0.38 0.007 (0.012) 0.47
DVT Time 0.079 (0.002) <0.001 0.008 (0.003) 0.002 0.009 (0.004) 0.01
Intercept 25(OH)D
Lowest 0.014 (0.004) 0.002 0.013 (0.004) 0.004 0.009 (0.004) 0.05
Middle (ref.) 0.0 0.0 0.0
Highest 0.011 (0.004) 0.006 0.012 (0.004) 0.004 0.010 (0.004) 0.02
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.002 (0.005) 0.61 0.002 (0.005) 0.66
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.004 (0.005) 0.39 0.004 (0.005) 0.34
PoA Time 0.026 (0.003) <0.001 0.023 (0.005) <0.001 0.023 (0.004) <0.001
Intercept 25(OH)D
Lowest 0.024 (0.007) 0.001 0.025 (0.007) 0.001 0.017 (0.007) 0.02
Middle (ref.) 0.0 0.0 0.0
Highest 0.026 (0.007) <0.001 0.026 (0.007) <0.001 0.022 (0.007) 0.002
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.009 (0.008) 0.27 0.009 (0.008) 0.27
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.003 (0.008) 0.71 0.003 (0.008) 0.71
RTV Time 0.003 (0.004) 0.43 0.004 (0.005) 0.46 0.005 (0.005) 0.38
Intercept 25(OH)D
Lowest 0.024 (0.008) 0.003 0.03 (0.009) 0.003 0.021 (0.009) 0.02
Middle (ref.) 0.0 0.0 0.0
Highest 0.018 (0.008) 0.03 0.017 (0.009) 0.06 0.020 (0.009) 0.03
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.007 (0.01) 0.48 0.005 (0.01) 0.61
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.003 (0.009) 0.78 0.002 (0.009) 0.80
CoA Time 0.091 (0.041) 0.03 0.107 (0.056) 0.06 0.122 (0.054) 0.03
Intercept 25(OH)D
Lowest 0.313 (0.087) <0.001 0.325 (0.093) 0.001 0.294 (0.092) 0.001
Middle (ref.) 0.0 0.0 0.0
Highest 0.029 (0.087) 0.74 0.039 (0.93) 0.68 0.134 (0.092) 0.14
Slope 25(OH)D 9 time n/a
Lowest 9 time 0.038 (0.104) 0.71 0.030 (0.10) 0.77
Middle 9 time (ref.) 0.0 0.0
Highest 9 time 0.033 (0.102) 0.75 0.040 (0.098) 0.68
SRT, simple reaction time; CRT, choice reaction time; DVT, digit vigilance task; PoA, power of attention; RTV, reaction time variability;
CoA, continuity of attention. Model 1 includes serum 25(OH)D and linear trend of time; in model 2 a linear trend of time by serum 25(OH)D
interaction is added; model 3 is further adjusted for education, sex, smoking status, current alcohol intake, renal impairment and number of
chronic diseases (0–1 diseases, 0; two diseases, 1; three and more diseases, 2). aEstimated b values (SE) of ﬁxed eﬀects using transformed longi-
tudinal data for all outcomes. Random eﬀects terms included both intercept and slopes of attention scores over time. Time in the study was
coded as baseline (0), 1.5-year follow-up (1) and 3-year follow-up (2). bSerum 25(OH)D was categorized in season-speciﬁc quartiles. Middle
quartiles (SQ2 and SQ3) were combined and served as the reference group.
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ever, the rate of change of all attention measures did
not vary across 25(OH)D groups, and no association
between 25(OH)D and odds of global incident cogni-
tive impairment or decline was found. In analyses
restricted to vitamin D supplements/medication non-
users, only the associations with the lowest season-
speciﬁc 25(OH)D group remained for both global
cognitive and attention-speciﬁc outcomes.
To our knowledge, this is the ﬁrst prospective study
to ﬁnd evidence for a U-shaped relationship between
25(OH)D and global cognitive function and attention
in the very old. Taken together, it could be hypothe-
sized that the neuroprotective eﬀects of vitamin D
mediated via expression of proteins that, for example,
attenuate the toxicity of reactive oxygen species [44] in
very old neurons are attained only at moderate but
not at low or high 25(OH)D concentrations.
Thus far, only four prospective studies of older
adults aged 65+ have examined the association between
25(OH)D and prevalent and incident global cognitive
impairment, and decline in attention and executive
function, with inconsistent results. A study of commu-
nity-dwelling older men [22] found limited evidence of
an independent association between lower 25(OH)D
concentration (≤19.9 ng/ml) and incident cognitive
impairment or decline in global and executive function.
A similar study involving community-dwelling older
women [23] reported that very low (<25 nM) and low
levels (<50 nM) of 25(OH)D were associated with an
increased risk of impaired global cognitive function
and decline [deﬁned by modiﬁed MMSE (3MS)], but
not with impaired executive function or decline. Two
further studies have also investigated these 25(OH)D
cut-points. The InCHIANTI study found that com-
pared with participants with suﬃcient 25(OH)D
(≥75 nM) the deﬁcient group (<25 nM) experienced a
substantial global (assessed by MMSE) and executive
cognitive decline (assessed by Trails A and B) over
6 years [24], whilst the Health, Aging and Body Com-
position Study conﬁrmed that lower 25(OH)D
(<50 nM) was associated with a greater cognitive
decline on the 3MS compared with suﬃcient 25(OH)D
(≥75 nM) over 4-year follow-up [25].
A similar global cognitive measure as in previous
studies was utilized, although diﬀerent serum 25(OH)
D cut-oﬀs were derived a posteriori [42], but no asso-
ciation between 25(OH)D and global incident impair-
ment or decline after adjustment for confounders was
detected. This lack of association may be due to the
age of our participants, reduced power to detect the
association, speciﬁc deﬁnition of cognitive change at
an individual level, and/or changed serum 25(OH)D
status over the 3 years of the study. Increased mortal-
ity amongst older women belonging to the lowest and
highest season-speciﬁc 25(OH)D quartiles as observed
in this cohort [45] could be one of the reasons for the
loss of analytical power. Incident impairment was
deﬁned as crossing the 25-point threshold of SMMSE
[31,32]. Although only ﬁve participants converted
from cognitively normal to impaired by losing one
point, a loss of <3 points may not represent a true
change at an individual level.
Reported adverse eﬀects of higher 25(OH)D
appeared to be driven by those taking prescribed vita-
min D medication [n = 139 (16.5%)],who may have
had prior (long-standing) vitamin D deﬁciency. There-
fore, a potential negative eﬀect of the highest 25(OH)
D quartile on cognitive functioning could be partly
driven by those with chronic vitamin D inadequacy
who through supplementation reached higher concen-
trations shortly before baseline assessments. Nonethe-
less our ﬁnding is in agreement with reports from the
NHANES III, a cross-sectional study of the non-insti-
tutionalized US population, aged 60–90 years, where
the worst performance on learning and memory tasks
was associated with the highest quintile of 25(OH)D
[21]. The Institute of Medicine Committee (2011) [7]
emphasized a curvilinear association between 25(OH)
D and non-skeletal health outcomes (e.g. all-cause
mortality, cancers, cardiovascular diseases) and cau-
tioned against the assumption that higher 25(OH)D
concentrations (>50 nM) inevitably provide greater
health beneﬁts. This has been conﬁrmed by a large
retrospective study that included older adults aged
75+ from Copenhagen general practices, which found
the lowest risk of all-cause mortality over 3 years was
associated with 50–60 nM of 25(OH)D [6].
About 27% of participants scored <26 SMMSE
points at baseline. There is therefore the possibility of
reverse causation (i.e. non-optimal 25(OH)D concen-
trations being a consequence of prevalent cognitive
impairment) [46], although excluding those with
dementia diagnosis in sensitivity analyses (n = 57) did
not change the U-shaped association between vitamin
D groups and baseline cognitive impairment after
adjusting for covariates (lowest, odds ratio 1.89, 95%
conﬁdence interval 1.18–3.03, P = 0.008; highest, 1.82,
1.11–2.97, P = 0.02; data not shown].
To assess change in attention/information process-
ing speed, attention ﬂuctuation and accuracy in rela-
tion to 25(OH)D, the CDR system, previously used in
dementia studies and clinical trials to discriminate
between various types of dementias and to detect
change in attention-speciﬁc cognitive domains pre and
post treatment with millisecond precision, was
employed [36,37,47]. Speciﬁcally, focused attention
(PoA) showed a clinically meaningful decline of 59 ms
over 6 months in very mildly impaired Alzheimer’s
© 2014 The Author(s).
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disease patients (MMSE >26) taking cholinesterase
inhibitors [48]. In the present study, participants in
the lowest and highest season-speciﬁc 25(OH)D quar-
tiles had overall worse focused attention and were by
~96 ms and ~86 ms slower (mean of raw scores),
respectively, than those in the middle group at
18 months’ follow-up. Future studies will determine
whether these attention deﬁcits relate to decline in glo-
bal cognition and interfere with daily functioning [49].
A small clinical trial of patients aged 65 and over
with a history of falls and 25(OH)D insuﬃciency
(≤12 ng/ml) showed an improvement of 0.4 s in CRT,
compared with the control group, 6 months after a
single intramuscular injection of vitamin D, which
increased the average serum 25(OH)D from 10.4 to
17.5 ng/ml – the latter within the middle quartiles
reported here to be associated with better attention
scores [50].
There are some limitations of our study mainly
related to loss to follow-up, use of a single measure of
25(OH)D and unknown 25(OH)D status prior to
baseline assessments. Although participants remaining
in the study had similar 25(OH)D concentrations to
those lost to follow-up, they were less cognitively
impaired and depressed, had fewer chronic diseases
and were less likely to take prescribed vitamin D med-
ication. In this cohort, prescribed vitamin D was a
signiﬁcant determinant of the highest, and less beneﬁ-
cial, serum 25(OH)D concentration. A single measure-
ment of circulating 25(OH)D may inadequately reﬂect
overall vitamin D status due to its cyclical nature [41],
although a preferred statistical method was used to
adjust for seasonal variability in 25(OH)D when only
one sample was available [42]. Generalization of our
ﬁndings may be limited to adults aged 85+ of white
ethnicity living at similar latitudes (55°N). Lastly,
observed statistically signiﬁcant worse attention scores
have limited interpretability and may not be clinically
meaningful and warrant treatment or intervention.
The strengths of our study include (i) its prospective
design, the representativeness of the cohort and inclu-
sion of the institutionalized older adults who were
assessed at residency to reduce attrition and selection
bias [28,29]; (ii) the inclusion of several cognition-
related covariates in multivariate analyses with the
entire cohort and ‘restricted cohort’; and (iii) imple-
mentation of global and attention-speciﬁc tests that
were validated and pilot-tested in this age group [40].
In summary, it was observed that both low and
high season-speciﬁc concentrations of 25(OH)D were
associated with increased risk of prevalent cognitive
impairment and worse attention-speciﬁc tasks
amongst older adults aged 85+, although the rates of
change were similar across vitamin D groups. Poorer
cognitive functioning in participants belonging to the
highest season-speciﬁc 25(OH)D group was driven by
those receiving vitamin D supplements/medication.
Future prospective studies should test the proposed
U-shaped relationship between serum 25(OH)D and
cognition in this age group and determine whether
other cognitive domains are aﬀected similarly by 25
(OH)D status.
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